| 000 | 01179 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250518012421.0 | ||
| 264 | 0 | _c20200427 | |
| 008 | 202004s 0 0 eng d | ||
| 022 | _a1099-1557 | ||
| 024 | 7 |
_a10.1002/pds.4697 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGirman, Cynthia J | |
| 245 | 0 | 0 |
_aConsiderations in characterizing real-world data relevance and quality for regulatory purposes: A commentary. _h[electronic resource] |
| 260 |
_bPharmacoepidemiology and drug safety _c04 2019 |
||
| 300 |
_a439-442 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aData Accuracy |
| 650 | 0 | 4 |
_aDrug Approval _xlegislation & jurisprudence |
| 650 | 0 | 4 |
_aPragmatic Clinical Trials as Topic _xlegislation & jurisprudence |
| 650 | 0 | 4 |
_aResearch Design _xstandards |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 |
_aUnited States Food and Drug Administration _xlegislation & jurisprudence |
| 700 | 1 | _aRitchey, Mary E | |
| 700 | 1 | _aZhou, Wei | |
| 700 | 1 | _aDreyer, Nancy A | |
| 773 | 0 |
_tPharmacoepidemiology and drug safety _gvol. 28 _gno. 4 _gp. 439-442 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/pds.4697 _zAvailable from publisher's website |
| 999 |
_c29129599 _d29129599 |
||